Despite effective antiretroviral therapy (ART), HIV-infected children on treatment have been observed to have cardiac abnormalities. We sought to determine the prevalence, types and factors associated with cardiac abnormalities among HIV-infected Ugandan children on combination ART.
We carried out a cross-sectional study from July 2012 to January 2013, at Joint Clinical Research Centre among HIV-infected children aged 1–18 years. Cardiac abnormalities were assessed using electrocardiography and echocardiography. CD4 counts, viral load and complete blood count were performed at enrollment. The prevalence of cardiac abnormalities was determined using simple proportions with the associated factors ascertained using logistic regression.
Among 285 children recruited, the median (interquartile range) age was 9 (6–13) years, 54% were female; 72% were on first line combination ART. Their mean (±SD) CD4 count was 1092 (±868.7) cells/mm3; median (interquartile range) viral load was 20 (20–76) copies/mL. Ninety-four percent had adherence to ART of more than 95%. Cardiac abnormalities were detected in 39 (13.7%) children. The most common abnormalities by electrocardiography and echocardiography were nonspecific T wave changes (4.6%) and pericardial disease (thickened pericardium with or without pericardial effusion; 2.8%), respectively. No factor assessed was found to be significantly associated occurrence of cardiac dysfunction.
The prevalence of cardiac dysfunction among the HIV-infected children on ART was 13.7%, which was high, with nonspecific T wave changes and pericardial disease being the most frequent abnormalities observed. No factor assessed was found to be associated with cardiac dysfunction.
From the *Department of Paediatrics, Makerere University College of Health Sciences; †Pediatric Cardiology Department, Uganda Heart Institute, Mulago Hospital; ‡Directorate of Research and Grants, Joint Clinical Research Centre (JCRC); and §Clinic Department, Makerere University-John Hopkins University (MUJHU) Care Limited, Kampala, Uganda.
Accepted for publication September 4, 2105.
This study was funded by the Fogarty International Center, the National Heart Lung and Blood Institute, and the Common Fund of the National Institutes of Health under Award Number R24TW008861, through MEPI-CVD. The authors have no conflicts of interest to disclose.
Address for correspondence: Judith Namuyonga, MMED, Uganda Heart Institute, Mulago Hospital, P.O. Box 7051 Kampala, Uganda. E-mail: firstname.lastname@example.org.